Active Biomarkers

MABDESIGN MEMBER

About us

Active Biomarkers offers its expertise for the evaluation of therapies in the detection & quantification of soluble Biomarkers & cell-based assays.

Know-how

Immunoassays, Flow cytometry, ELISpot, Immunogenicity

Business offer

The largest immuno-assay platform offer in Europe (MSD, Ella, Luminex, Simoa HD-1, Simoa SP-X, VIDAS, Gyros).
Monitoring the immune response in a regulatory compliant setting is our expertise at Active Biomarkers. We support preclinical and clinical studies to evaluate the safety and efficacy of monoclonal antibodies (mAbs), immune-checkpoint inhibitors, vaccines, Antibody Drug Conjugates (ADCs), Chimeric Antigen Receptor T cells (CAR-T cells) and several other candidate immunotherapies.

Field of application
  • antibodies
  • cellular immunotherapy
  • immunomodulators
  • biomarkers
Therapeutic application
  • hematology
  • infectiology
  • immunology
  • oncology
  • Neurological diseases

Expertise

  • Functional effects
  • ADCC, ADCP & CDC
  • Pharmacology & Biological activity
  • PK/PD bioavailability
  • Mode of Action
  • Therapeutic efficacy
  • Safety
  • Immunogenicity
  • Mechanism/Function
  • Mechanism of action
  • Safety
  • PK/PD features
  • Indication Identification
  • Exploratory toxicology
  • Drug-Target interaction
  • Level of response duration
  • Specificity
  • Surrogate markers
  • Research exploratory Companion biomarkers
  • Human biomarkers
  • Predictive biomarkers
  • Treatment efficacy
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Predictive biomarkers
  • Treatment efficacy
  • Population stratification
  • Risk/benefit profile
  • Disease progression / follow-up
  • Safety
  • PK/PD features
  • Surrogate markers
  • Disease progression monitoring
  • Post-Market Surveillance
  • Treatment efficacy
  • Treatment monitoring
  • Toxicity

Category

  • Service

Contact